BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 112974
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.112974
Endoscopic ultrasound-guided radiofrequency ablation: A game-changer in pancreatic cancer treatment
Chuan Tong, Yi-Qing Hui, Jun-Rong Wang
Chuan Tong, Yi-Qing Hui, School of Nursing, Jilin Medical University, Jilin 132000, Jilin Province, China
Jun-Rong Wang, Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, Changchun 130022, Jilin Province, China
Co-corresponding authors: Yi-Qing Hui and Jun-Rong Wang.
Author contributions: Tong C contributed to the writing and editing of the manuscript, Hui YQ and Wang JR contributed to the literature search, designed the overall concept and outline of the manuscript as co-corresponding authors; all authors have read and approve the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Corresponding author: Jun-Rong Wang, MD, PhD, Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130022, Jilin Province, China. junrongwang_2019@yeah.net
Received: August 11, 2025
Revised: November 25, 2025
Accepted: January 4, 2026
Published online: March 15, 2026
Processing time: 213 Days and 6.2 Hours
Core Tip

Core Tip: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising minimally invasive treatment for pancreatic cancer, particularly in patients with unresectable or high-risk tumors. Recent technological advancements have improved procedural precision and safety, demonstrating high technical success rates and potential symptom palliation. When combined with chemotherapy, EUS-RFA may offer enhanced tumor control and survival benefits, though long-term clinical outcomes require further investigation. Additionally, the immunomodulatory effects of EUS-RFA may augment systemic anti-tumor immunity, offering a potential synergy with immunotherapies. However, larger randomized controlled trials and standardized protocols are needed to fully establish its role in the clinical management of pancreatic cancer.